テキサスにおける過体重の臨床試験
テキサス内の拠点で、過体重に関する55件の研究が参加者を募集しています。
テキサス内の都市
- San Antonio34件の研究
- Houston33件の研究
- Dallas20件の研究
- Austin18件の研究
- Grand Prairie11件の研究
- The Woodlands10件の研究
- Sugar Land10件の研究
- Pharr10件の研究
- El Paso8件の研究
- Brownsville7件の研究
- Amarillo7件の研究
- Mesquite6件の研究
- Corpus Christi5件の研究
- Fort Worth4件の研究
- Wichita Falls3件の研究
- Garland3件の研究
- Lubbock3件の研究
- Tyler3件の研究
公式研究テキスト（英語）
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Amarillo Medical Specialists /ID# 282380, Amarillo
- Elligo Clinical Research Center /ID# 282166, Austin
- Velocity Clinical Research - Dallas /ID# 282734, Dallas
- 他2件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/10/01更新 · NCT07752979A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
- Kailera Clinical Site, San Antonio
被験者募集中第1相健康なボランティア歓迎
18歳〜85歳 · 全性別 · 2026/10/01更新 · NCT07793929AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- UT Southwestern Med Center, Dallas
- PlanIt Research, PLLC, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- DM Clinical, Houston
- DM Clinical, San Antonio
- The Texas Liver Institute, San Antonio
- 他3件
被験者募集中第3相
8歳〜18歳 · 全性別 · 2026/09/30更新 · NCT07253285AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Amarillo Medical Specialists, Amarillo
- North Texas Endocrine Center, Dallas
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07720271A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
- Amarillo Med Spec LLP, Amarillo
- Texas Diabetes & Endocrinology, Austin
- Pinnacle Clinical Research, Brownsville
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07668414A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- IMA Clinical Research Austin, Austin
- Headlands Horizons, LLC dba Headlands Research-Brownsville, Brownsville
- Cedar Health Research - Texas Native Health, Dallas
- 他10件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07794579Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D
- Endeavor Clinical Trials, San Antonio
被験者募集中第1相
18歳〜65歳 · 全性別 · 2026/09/28更新 · NCT07399678A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
- PlanIt Research, LLC (Monitoring Room), Houston
- PlanIt Research, LLC, Houston
- VIP Trials, San Antonio
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07595549A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07776509A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Dell Children's Medical Center - PIN, Austin
- Driscoll Children's Hospital, Corpus Christi
- McGovern Medical School, Houston
- 他4件
被験者募集中第3相
6歳〜17歳 · 全性別 · 2026/09/24更新 · NCT06672549Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Research of San Antonio, San Antonio
- Southern Star Research Institute, San Antonio
- Tyler Research Institute, Tyler
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Research of San Antonio, San Antonio
- Southern Star Research Institute, San Antonio
- Tyler Research Institute, Tyler
被験者募集中第3相
18歳〜70歳 · 全性別 · 2026/09/24更新 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- The University of Texas Health Science Center at Houston, Bellaire
- Velocity Clinical Research, Dallas, Dallas
- UT Southwestern Medical Center, Dallas
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- PharmaTex Research, LLC, Amarillo
- Austin Heart, Austin
- Velocity Clinical Research - Austin, Austin
- 他22件
被験者募集中第3相
45歳〜99歳 · 全性別 · 2026/09/22更新 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- UT Southwestern Medical Center, Dallas
- Juno Research, Houston
- Activian Clinical Research, Kingwood
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- FutureSearch Trials of Neurology, Austin
- Sleep Therapy Research Center, San Antonio
- Consano Clinical Research, LLC, Shavano Park
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07369011A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- IMA Clinical Research Austin, Austin
- FutureSearch Trials of Dallas, Dallas
- PlanIt Research, PLLC, Houston
- 他2件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/22更新 · NCT07589608Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- JCCT - Juno Bellaire Site, Bellaire
- Epic Medical Research - DeSoto, DeSoto
- Valley Institute of Research - Fort Worth, Fort Worth
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- IMA Clinical Research Austin, Austin
- Private Practice - Dr. Osvaldo A. Brusco, Corpus Christi
- Velocity Clinical Research, Dallas, Dallas
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07282600A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, DeSoto
- Research Site, El Paso
- Research Site, Houston
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07784270Semaglutide for Post-Smoking Cessation Weight Management
- The University of Texas at Austin, Austin
- The University of Texas Health Science Center at Houston, Houston
被験者募集中第2相健康なボランティア歓迎
18歳〜75歳 · 全性別 · 2026/09/21更新 · NCT06173778A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Austin
- AURORA-1 Clinical Site, Brownsville
- AURORA-1 Clinical Site, DeSoto
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Austin
- AURORA-2 Clinical Site, Brownsville
- AURORA-2 Clinical Site, DeSoto
- 他10件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Headlands Research Brownsville, Brownsville
- Velocity Clinical Research, Dallas
- South Texas Research Institute - Edinburg, Edinburg
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351058A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Juno Research, Houston
- Southern Endocrinology Associates, Mesquite
- Texas Diabetes & Endocrinology, P.A., Round Rock
- 他2件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/14更新 · NCT06897475A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Bellaire Clinical Research, LLC, Bellaire
- South Texas Research Institute - Brownsville, Brownsville
- South Texas Clinical Research, Corpus Christi
- 他8件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/14更新 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Austin
- ACCOMPLISH-2 Research Site, Farmers Branch
- ACCOMPLISH-2 Research Site, Houston
- 他4件
被験者募集中第3相健康なボランティア歓迎
18歳〜79歳 · 全性別 · 2026/09/11更新 · NCT07654374AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Epic Medical Research, DeSoto
- Advanced Neurology Epilepsy and Sleep Center ANESC, El Paso
- Biorhythms Center for Integrative Sleep Medicine, El Paso
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/11更新 · NCT07571005Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Cedar Health Research, Dallas
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07770841AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
- Epic Medical Research, DeSoto
- Advanced Neurology Epilepsy and Sleep Center ANESC, El Paso
- Biorhythms Center for Integrative Sleep Medicine, El Paso
- 他3件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07571109A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Mercy Family Clinic, Dallas
- Velocity Clinical Research, Dallas, Dallas
- Biopharma Informatic, LLC, Houston
- 他5件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT07215559A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- IMA Clinical Research Austin, Austin
- Velocity Clinical Research, Dallas, Dallas
- FutureSearch Trials of Dallas, Dallas
- 他3件
被験者募集中第2相
18歳〜75歳 · 全性別 · 2026/09/08更新 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Bellaire Dermatology Associates, Bellaire
- Modern Research Associates, PLLC, Dallas
- Center for Clinical Studies, Houston
- 他3件
被験者募集中第4相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06857942A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity
- ICON, San Antonio
被験者募集中第1相健康なボランティア歓迎
18歳〜55歳 · 全性別 · 2026/09/04更新 · NCT07767175Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Amarillo
- Kailera Clinical Site, Bellaire
- Kailera Clinical Site, DeSoto
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Elligo Clinical Research Center, Austin
- Johnson County Clinical Trials Juno Bellaire, Bellaire
- Cedar Health Research, LLC, Dallas
- 他9件
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684235Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Elligo Clinical Research Center, Austin
- Johnson County Clinical Trials Juno Bellaire, Bellaire
- Osvaldo A Brusco MD PA, Corpus Christi
- 他2件
被験者募集中第3相
18歳〜99歳 · 全性別 · 2026/09/03更新 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Amarillo
- Kailera Clinical Site, Brownsville
- Kailera Clinical Site, DeSoto
- 他5件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/03更新 · NCT07284901A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
- ICON Early Phase Services, LLC, San Antonio
被験者募集中第1相健康なボランティア歓迎
18歳〜65歳 · 全性別 · 2026/09/01更新 · NCT07654972ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。